Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL

Blood (2024) 144 (Supplement 1): 634.

https://doi.org/10.1182/blood-2024-203756

Published: 2024

Journal Articles

Treatment Strategies and Outcomes of the Rare Histiocytic Disorders: Long-Term Results of the International Rare Histiocytic Disorders Registry (IRHDR)

Blood (2024) 144 (Supplement 1): 3909.

https://doi.org/10.1182/blood-2024-205959

Published: 2024

Journal Articles

Prognostic Importance of Cytogenetic Subgroups in Relapse Risk Stratification in Children and Young Adults with First Relapsed B-ALL: A Children's Oncology Group Study AALL1331

Teena Bhatla, Laura Hogan, Xinxin Xu, Lingyun Ji, Andrew J. Carroll, Nyla A. Heerema, Mary Shago, Lia Gore, James A. Whitlock, Stephen P. Hunger, Mignon L. Loh, Patrick A. Brown

Blood (2022) 140 (Supplement 1): 3476–3477.

https://doi.org/10.1182/blood-2022-166523

Published: 2022

Journal Articles

ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition

Paul G. Kemps, Jennifer Picarsic, Benjamin H. Durham, Zofia Hélias-Rodzewicz, Laura Hiemcke-Jiwa, Cor van den Bos, Marianne D. van de Wetering, Carel J. M. van Noesel, Jan A. M. van Laar, Robert M. Verdijk, Uta E. Flucke, Pancras C. W. Hogendoorn, F. J. Sherida H. Woei-A-Jin, Raf Sciot, Andreas Beilken, Friedrich Feuerhake, Martin Ebinger, Robert Möhle, Falko Fend, Antje Bornemann, Verena Wiegering, Karen Ernestus, Tina Méry, Olga Gryniewicz-Kwiatkowska, Bozenna Dembowska-Baginska, Dmitry A. Evseev, Vsevolod Potapenko, Vadim V. Baykov, Stefania Gaspari, Sabrina Rossi, Marco Gessi, Gianpiero Tamburrini, Sébastien Héritier, Jean Donadieu, Jacinthe Bonneau-Lagacherie, Claire Lamaison, Laure Farnault, Sylvie Fraitag, Marie-Laure Jullié, Julien Haroche, Matthew Collin, Jackie Allotey, Majid Madni, Kerry Turner, Susan Picton, Pasquale M. Barbaro, Alysa Poulin, Ingrid S. Tam, Dina El Demellawy, Brianna Empringham, James A. Whitlock, Aditya Raghunathan, Amy A. Swanson, Mariko Suchi, Jon M. Brandt, Nabeel R. Yaseen, Joanna L. Weinstein, Irem Eldem, Bryan A. Sisk, Vaishnavi Sridhar, Mandy Atkinson, Lucas R. Massoth, Jason L. Hornick, Sanda Alexandrescu, Kee Kiat Yeo, Kseniya Petrova-Drus, Stephen Z. Peeke, Laura S. Muñoz-Arcos, Daniel G. Leino, David D. Grier, Robert Lorsbach, Somak Roy, Ashish R. Kumar, Shipra Garg, Nishant Tiwari, Kristian T. Schafernak, Michael M. Henry, Astrid G. S. van Halteren, Oussama Abla, Eli L. Diamond, Jean-François Emile

Blood (2022) 139 (2): 256–280.

https://doi.org/10.1182/blood.2021013338

Published: 2022

Includes: Supplemental data

Journal Articles

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs): A Report from Children's Oncology Group Study AALL1331

Patrick A. Brown, Lingyun Ji, Xinxin Xu, Meenakshi Devidas, Laura Hogan, Teena Bhatla, Michael Borowitz, Elizabeth A. Raetz, Lia Gore, James A. Whitlock, Stephen P. Hunger, Mignon L. Loh

Blood (2021) 138 (Supplement 1): 363.

https://doi.org/10.1182/blood-2021-147946

Published: 2021

Journal Articles

Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) in Combination with UK ALL-R3 Induction Chemotherapy for Children, Adolescents and Young Adults with Relapsed Acute Lymphoblastic Leukemia (ALL): A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial

Blood (2021) 138 (Supplement 1): 3402.

https://doi.org/10.1182/blood-2021-149365

Published: 2021

Journal Articles

Tisagenlecleucel Therapy Is Safe and Effective for Children with Down Syndrome with ALL in First Relapse

Joerg Krueger, Johann K Hitzler, Stephanie Audrey Mourad, Mylene Bassal, Elizabeth Cairney, Bruce N. Crooks, Angela Punnett, Sarah Alexander, Muhammad Ali, Henrique Bittencourt, James A. Whitlock, Sumit Gupta

Blood (2021) 138 (Supplement 1): 4820.

https://doi.org/10.1182/blood-2021-153262

Published: 2021

Journal Articles

Dabrafenib, Alone or in Combination with Trametinib, in Pediatric Patients with BRAF V600 Mutation-Positive Langerhans Cell Histiocytosis

James A. Whitlock, Birgit Geoerger, Michael Roughton, Jeea Choi, Lisa Osterloh, Mark Russo, Darren Hargrave

Blood (2021) 138 (Supplement 1): 3618.

https://doi.org/10.1182/blood-2021-147377

Published: 2021

Journal Articles

Cytogenetic Subgroups Drive Risk Stratification and Response to Chemotherapy and Blinatumomab in Children and Young Adults with Relapsed B-ALL: A Children's Oncology Group Study

Teena Bhatla, MD, Laura Hogan, MD, Xinxin Xu, MS, Lingyun Ji, Andrew J Carroll, PhD, Nyla A Heerema, PhD, Mary Shago, PhD, Lia Gore, MD, James A. Whitlock, MD, Stephen P Hunger, MD, Mignon L. Loh, MD, Patrick A. Brown, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-136364

Published: 2020

Journal Articles

Go with the flow: simplified MRD in LMIC ALL

James A. Whitlock

Blood (2020) 135 (17): 1414–1415.

https://doi.org/10.1182/blood.2020005292

Published: 2020

Journal Articles

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331

Patrick A. Brown, MD, Lingyun Ji, PhD, Xinxin Xu, MS, Meenakshi Devidas, PhD, Laura Hogan, MD, Michael J. Borowitz, MD PhD, Elizabeth A. Raetz, MD, Gerhard Zugmaier, Elad Sharon, MD MPH, Lia Gore, MD, James A. Whitlock, MD, Michael A. Pulsipher, MD, Stephen P. Hunger, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_2): LBA-1.

https://doi.org/10.1182/blood-2019-132435

Published: 2019

Journal Articles

High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study from Ontario, Canada

Sumit Gupta, MD, Sarah Alexander, MD, Sue Zupanec, RN, Uma Athale, MDMBBS,MSc, Mylene Bassal, MD, Ethan Edwards, Paul J. Gibson, MD, Donna Johnston, MDFRCPC, Stacey Marjerrison, MD, Alexander Zorzi, MD, Johann K. Hitzler, MD, Ahmed Naqvi, MD, Angela Punnett, MD, James A. Whitlock, MD, Stephan A. Grupp, MD PhD, Shannon L. Maude, MD PhD, Joerg Krueger, MD

Blood (2018) 132 (Supplement 1): 1410.

https://doi.org/10.1182/blood-2018-99-115593

Published: 2018

Journal Articles

Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease

Oussama Abla, Eric Jacobsen, Jennifer Picarsic, Zdenka Krenova, Ronald Jaffe, Jean-Francois Emile, Benjamin H. Durham, Jorge Braier, Frédéric Charlotte, Jean Donadieu, Fleur Cohen-Aubart, Carlos Rodriguez-Galindo, Carl Allen, James A. Whitlock, Sheila Weitzman, Kenneth L. McClain, Julien Haroche, Eli L. Diamond

Blood (2018) 131 (26): 2877–2890.

https://doi.org/10.1182/blood-2018-03-839753

Published: 2018

Journal Articles

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia

Alan S. Wayne, Nirali N. Shah, Deepa Bhojwani, Lewis B. Silverman, James A. Whitlock, Maryalice Stetler-Stevenson, Weili Sun, Meina Liang, Jie Yang, Robert J. Kreitman, Mark C. Lanasa, Ira Pastan

Blood (2017) 130 (14): 1620–1627.

https://doi.org/10.1182/blood-2017-02-749101

Published: 2017

Includes: Supplemental data

Journal Articles

Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition

Neerav Shukla, MD, Maureen M. O'Brien, MD, Lewis B. Silverman, MD, Melinda Pauly, MD, Cynthia Wetmore, MD PhD, Mignon L. Loh, MD, James A. Whitlock, MD, Patrick Brown, MD, Blythe Thomson, MD, Stephen J. Blakemore, PhD, Scott Daigle, Patricia Pimentel, Nigel J. Waters, PhD, Andrei V Krivstov, PhD, Richard Koche, PhD, Scott A. Armstrong, MD PhD, Peter T Ho, PhD MD, Lia Gore, MD

Blood (2015) 126 (23): 3792.

https://doi.org/10.1182/blood.V126.23.3792.3792

Published: 2015

Journal Articles

Re-Induction Outcome for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Therapeutic Advances in Childhood Leukemia Consortium

Weili Sun, MDPhD, Jemily Malvar, MS, Richard Sposto, PhD, Anupam Verma, MD, Jennifer J. Wilkes, MD, Robyn M. Dennis, MD, Kenneth Matthew Heym, MD, Elena Eckroth, CCRC, Jeannette Vandergiesse, BA, CCRP, Paul S. Gaynon, MD, Alan S. Wayne, MD, James A. Whitlock, MD

Blood (2015) 126 (23): 3760.

https://doi.org/10.1182/blood.V126.23.3760.3760

Published: 2015

Journal Articles

Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group

Blood (2014) 123 (1): 70–77.

https://doi.org/10.1182/blood-2013-06-509463

Published: 2014

Includes: Supplemental data

Journal Articles

AAML0523: A Report From the Children's Oncology Group On the Efficacy of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Myeloid Leukemia

Todd Cooper, DO, Todd A. Alonzo, PhD, Robert B. Gerbing, M.A., John Perentesis, MD, James A. Whitlock, MD, Jeffrey W. Taub, MD, Terzah M. Horton, MD, PhD, Alan S. Gamis, MD, MPH, Bassem I. Razzouk, MD

Blood (2012) 120 (21): 3604.

https://doi.org/10.1182/blood.V120.21.3604.3604

Published: 2012

Journal Articles

Acute Lymphoblastic Leukemia in Children with Down Syndrome: A Report From the Ponte Di Legno Study Group,

Blood (2011) 118 (21): 3579.

https://doi.org/10.1182/blood.V118.21.3579.3579

Published: 2011

Journal Articles

Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2

Elizabeth A. Raetz, MD, Mitchell S. Cairo, MD, Michael J. Borowitz, MD, PhD, Xiaomin Lu, PhD, Meenakshi Devidas, PhD, Joel M. Reid, PhD, David M. Goldenberg, ScD, MD, William A Wegener, MD, PhD, James A. Whitlock, MD, Peter C. Adamson, MD, Stephen P Hunger, MD, William L. Carroll, MD

Blood (2011) 118 (21): 573.

https://doi.org/10.1182/blood.V118.21.573.573

Published: 2011

NARROW

TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL

Treatment Strategies and Outcomes of the Rare Histiocytic Disorders: Long-Term Results of the International Rare Histiocytic Disorders Registry (IRHDR)

Prognostic Importance of Cytogenetic Subgroups in Relapse Risk Stratification in Children and Young Adults with First Relapsed B-ALL: A Children's Oncology Group Study AALL1331

ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs): A Report from Children's Oncology Group Study AALL1331

Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) in Combination with UK ALL-R3 Induction Chemotherapy for Children, Adolescents and Young Adults with Relapsed Acute Lymphoblastic Leukemia (ALL): A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial

Tisagenlecleucel Therapy Is Safe and Effective for Children with Down Syndrome with ALL in First Relapse

Dabrafenib, Alone or in Combination with Trametinib, in Pediatric Patients with BRAF V600 Mutation-Positive Langerhans Cell Histiocytosis

Cytogenetic Subgroups Drive Risk Stratification and Response to Chemotherapy and Blinatumomab in Children and Young Adults with Relapsed B-ALL: A Children's Oncology Group Study

Go with the flow: simplified MRD in LMIC ALL

High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study from Ontario, Canada

Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia

Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition

Re-Induction Outcome for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Therapeutic Advances in Childhood Leukemia Consortium

Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group

AAML0523: A Report From the Children's Oncology Group On the Efficacy of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia in Children with Down Syndrome: A Report From the Ponte Di Legno Study Group,

Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only